DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the market capitalisation of Samrat Pharmachem Ltd?

Samrat Pharmachem Ltd has a market capitalisation of approximately ₹76 crore.

Samrat Pharmachem Ltd

SAMRATPHARMACHEMLTD·NSE·Healthcare

₹0.00▲ +0.00 (+0.00%)

⚠️Trading suspended. Not a live price.

Healthcare · Pharmaceuticals

A steady, established business

52W₹190

₹389-95%

Open

—

High

—

Low

—

Prev Close

—

Volume

—

VWAP

—

Snapshot

Key fundamentals

Market Cap

₹76 Cr

P/E Ratio

N/A

P/B Ratio

1.15

EPS

₹23.01

Book Value

₹220.67

ROE

-4.73%Weak

ROCE

13.00%Decent

Dividend Yield

0.39%

Debt / Equity

0.16Low

Face Value

₹10.00

52W High

₹389.00

52W Low

₹190.00

Sector

Healthcare

Industry

Pharmaceuticals

Fairly Valued

None moatMedium uncertainty

Fair value estimate

₹209

No recent traded price

BearFair valueBull

₹178₹209₹241

/100

Business quality — Watch the fundamentals

Growth 50Profitability 1Efficiency 25Valuation 92

Plain English

Our view

A steady, established business
Low debt relative to equity
Weak returns on equity (-5%)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

—

ROE

-4.7%Weak

Above 15% is considered healthy for Indian equities

ROCE

13.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.16Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹76 Cr

P/B

1.15

EPS

₹23.01

Div Yield

0.39%

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

N/A

No P/E

Growth

Shrinking

-2% rev CAGR

Profitability

Loss-making

-4.7% ROE

Financial health

Rock solid

D/E 0.16

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover—

Trades—

VWAP—

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

-2.3%

+10.1%

10Y

+16.5%

Profit

—

10Y

—

EPS

-49.3%

-16.5%

10Y

+21.9%

Profile

Pros

Stock is trading at 1.15 times its book value

Watch-outs

Cons

Company has low interest coverage ratio.
The company has delivered a poor sales growth of 10.1% over past five years.
Company has a low return on equity of 2.40% over last 3 years.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

49%

Promoter

Promoters

49.1%0.00

Public

41.8%+0.25

FII / FPI

3.2%0.00

DII

0.0%0.00

Others

5.9%

Total shareholders

6,311-177 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter49.09%

FII3.24%

Public41.75%

Others5.92%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1992, Samrat Pharmachem Ltd does manufacturing and selling of chemicals[1]